JP2008044894A - Metabolic syndrome ameliorative agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a prophylactic and/or ameliorative agent for metabolic syndrome or diseases caused thereby, to provide a functional food containing the agent, and to provide application methods using them. <P>SOLUTION: The prophylactic and/or ameliorative agent for metabolic syndrome or diseases caused thereby comprises coenzyme Q10 as active ingredient. The functional food contains coenzyme Q10 as the active ingredient, having the effects of ameliorating metabolic syndrome or such diseases caused thereby and having the effects of preventing and/or ameliorating metabolic syndrome or the above-mentioned diseases. A method for ameliorating metabolic syndrome or the above-mentioned diseases comprising taking-in a composition containing coenzyme Q10 as the active ingredient, and method(s) for preventing and/or ameliorating metabolic syndrome or the above-mentioned diseases, are also provided, respectively. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention relates to a metabolic syndrome, a preventive and / or ameliorating agent for diseases caused by metabolic syndrome, or a functional food comprising coenzyme Q10 as an active ingredient. Further, use of coenzyme Q10 for producing a metabolic syndrome or a composition for preventing and / or improving a disease caused by metabolic syndrome, coenzyme Q10 for preventing and / or improving a disease caused by metabolic syndrome or metabolic syndrome About the use of.

  Coenzyme Q10 is a benzoquinone derivative and is widely distributed in the living world, so it was named ubiquinone (oxidized coenzyme Q10). A hydroquinone form obtained by reducing this by two electrons is ubiquinol (reduced coenzyme Q10). Although many homologues exist depending on the length (n) of the isoprenoid side chain (n = 1 to 12), the main homologue is determined by the species because it is biosynthesized. In mammals, n = 9 and 10 are mainly used. For example, n = 9 is often used in mice and rats, and n = 10 is often used in rabbits. For humans, n = 10.

  Coenzyme Q10 is a physiological component that exists as a constituent component of the mitochondrial electron transfer system in cells in the living body, and plays a role as a transfer component in the electron transfer system by repeating oxidation and reduction in the living body. Since coenzyme Q10 exhibits energy production and antioxidant activity in vivo, its usefulness is widely known. Coenzyme Q10 is a molecule that is biosynthesized in the human body, but it has been reported that the amount of biosynthesis decreases with age, or that the amount of coenzyme Q10 in the body in various diseases is decreased. In such diseases, external supply of coenzyme Q10 has yielded good results. Furthermore, it is considered that coenzyme Q10 needs to be replenished not only at the time of illness but also at normal times such as when the elderly or physically fatigued.

  Oxidized coenzyme Q10 is used for pharmaceutical use as a congestive heart failure drug. In addition to vitamins, as with vitamins, nutritional supplements, nutritional supplements, senile diseases such as dementia, usefulness for allergic diseases, and increased exercise capacity have also been reported, and their safety It is said to be a useful means of nutrition because it is expensive.

  On the other hand, in recent years, the number of patients with so-called metabolic syndrome (multiple risk factor syndrome) that has lifestyle-related diseases such as hyperlipidemia, hypertension, diabetes, and obesity continues to increase in Japan due to lifestyle changes. It is a problem. The reason is that this syndrome tends to cause and develop arteriosclerosis and causes myocardial infarction and stroke. The above four lifestyle-related diseases are all major risk factors for arteriosclerosis and commonly increase the production of active oxygen (Non-Patent Documents 1 and 2). Reactive oxygen is thought to cause arteriosclerosis by damaging the function of vascular endothelial cells directly or through oxidation of low density lipoprotein (LDL) and further promoting lipid accumulation in the vascular wall. Therefore, in the metabolic syndrome in which lifestyle-related diseases are accumulated, the active oxygen should be further increased (oxidative stress state), and arteriosclerotic lesions are thought to develop and progress.

To date, dietary restrictions and exercise therapy have been the main treatment and improvement methods for metabolic syndrome, and there are no specific treatments for diseases (diabetes, blood pressure lowering, hyperlipidemia, etc.). However, in reality, there is no preventive and / or ameliorating agent for metabolic syndrome or functional food.
Under these circumstances, development of a preventive and / or ameliorating agent for diseases caused by metabolic syndrome or metabolic syndrome, or a functional food has been strongly desired.
Japanese clinical practice, 62, (6) 1021-1028 (2004) Japanese clinical practice, 62, (6) 1029-1036 (2004)

  An object of the present invention is to provide a metabolic syndrome, a preventive and / or ameliorating agent for diseases caused by metabolic syndrome, or a functional food, or a production method thereof, and further provide an application method using the same. is there.

As a result of intensive studies to solve the above-mentioned problems, the present inventors have found that coenzyme Q10 has an effect of preventing and / or improving metabolic syndrome or a disease caused by metabolic syndrome, and completed the present invention.
Specifically, it has been found that taking or applying a composition containing coenzyme Q10 as an active ingredient can prevent and / or improve metabolic syndrome or a patient having a disease caused by metabolic syndrome without any side effects. The present invention has been completed.
That is, the present invention
(1) Metabolic syndrome containing coenzyme Q10 as an active ingredient or a preventive and / or ameliorating agent for diseases caused by metabolic syndrome;
(2) Metabolic syndrome containing coenzyme Q10 as an active ingredient or a functional food having a preventive and / or ameliorating effect on diseases caused by metabolic syndrome;
(3) Use of coenzyme Q10 for producing a metabolic syndrome or a composition for preventing and / or ameliorating a disease caused by metabolic syndrome;
(4) Use of coenzyme Q10 for prevention and / or amelioration of metabolic syndrome or a disease caused by metabolic syndrome;
(5) Ingesting or applying a composition containing coenzyme Q10 as an active ingredient, metabolic syndrome or a method for preventing and / or ameliorating a disease caused by metabolic syndrome;
(6) The preventive and / or ameliorating agent according to (1), wherein the disease caused by metabolic syndrome is arteriosclerosis;
(7) The functional food according to the above (2), wherein the disease caused by metabolic syndrome is arteriosclerosis;
(8) Use of coenzyme Q10 according to (4) above, wherein the disease caused by metabolic syndrome is arteriosclerosis;
(9)
The prevention or amelioration method according to the above (5), wherein the disease caused by metabolic syndrome is arteriosclerosis;
(10) Prevention or prevention of metabolic syndrome or a disease caused by metabolic syndrome by improving at least one symptom of hypertension, oxidative stress, inflammation, or insulin resistance containing coenzyme Q10 as an active ingredient Improver;
About.
Furthermore, the present invention provides:
(11) An agent for preventing and / or improving metabolic syndrome accompanied by an enhancement of at least one of oxidized LDL value, 8-hydroxydeoxyguanosine value, 3-nitrotyrosine value, and 3-chlorotyrosine value, comprising coenzyme Q10 as an active ingredient;
(12) An agent for improving metabolic syndrome accompanied by an enhancement of at least one of oxidized LDL value, 8-hydroxydeoxyguanosine value, 3-nitrotyrosine value, and 3-chlorotyrosine value, comprising coenzyme Q10 as an active ingredient;
(13) Antihypertensive agent caused by metabolic syndrome containing coenzyme Q10 as an active ingredient;
(14) An inhibitor of high 8-hydroxydeoxyguanosine value caused by metabolic syndrome containing coenzyme Q10 as an active ingredient;
(15) An inhibitor of DNA oxidative damage caused by metabolic syndrome, comprising coenzyme Q10 as an active ingredient;
(16) A preventive agent for arteriosclerosis caused by increased oxidation of metabolic syndrome containing coenzyme Q10 as an active ingredient;
(17) An inhibitor of high oxidized LDL value containing coenzyme Q10 as an active ingredient;
(18) An oxidative stress inhibitor containing coenzyme Q10 as an active ingredient;
(19) A preventive agent for arteriosclerosis caused by metabolic syndrome containing coenzyme Q10 as an active ingredient;
(20) An inhibitor of high 3-nitrotyrosine value and 3-chlorotyrosine value caused by metabolic syndrome containing coenzyme Q10 as an active ingredient;
(21) An inhibitor of a high reactive nitrogen oxide value caused by metabolic syndrome containing coenzyme Q10 as an active ingredient;
(22) An inhibitor of the progression of arteriosclerosis caused by metabolic syndrome containing coenzyme Q10 as an active ingredient;
(23) Inhibitor of high insulin level caused by metabolic syndrome containing coenzyme Q10 as an active ingredient;
(24) An agent for improving diabetes that develops as a metabolic syndrome containing coenzyme Q10 as an active ingredient;
(25) Preventive agent for diabetes caused by metabolic syndrome containing coenzyme Q10 as an active ingredient;
(26) A high-sensitivity CRP value inhibitor containing coenzyme Q10 as an active ingredient;
(27) an agent for improving myocardial infarction and / or diabetes comprising coenzyme Q10 as an active ingredient;
(28) A prophylactic agent for myocardial infarction and / or diabetes caused by metabolic syndrome comprising coenzyme Q10 as an active ingredient;
(29) The agent according to (11) to (28) above, which is taken orally;
(30) A mode in which the mode of the “agent” according to the above (11) to (29) is replaced with “functional food”;
(31) The aspect which rewritten the aspect of the "agent" as described in said (11)-(29) to the aspect of "use of coenzyme Q10 for manufacturing the composition for prevention and / or improvement";
(32) A mode in which the mode of the “agent” according to the above (11) to (29) is rewritten into a mode of “use of coenzyme Q10 for prevention and / or improvement”;
About.

  According to the present invention, a preventive and / or ameliorating agent for metabolic syndrome or a disease caused by metabolic syndrome, a preventive and / or ameliorating effect for a disease caused by metabolic syndrome or metabolic syndrome, comprising coenzyme Q10 as an active ingredient Functional foods, cosmetics, and further, use of coenzyme Q10 for adjusting metabolic syndrome or a composition for preventing and / or improving diseases caused by metabolic syndrome, and a composition containing the compound as an active ingredient It is possible to provide a method for preventing and / or improving a metabolic syndrome or a disease caused by a metabolic syndrome characterized by ingesting or applying an object.

  The present invention will be specifically described below. Coenzyme Q10 used in the present invention is not limited in its origin and production method as long as it is coenzyme Q10 that can be taken or edible as a medicine or food, but a commercially available product is preferred. Further, it may be a compound that converts to coenzyme Q10 in vivo, and it does not matter if it contains reduced coenzyme Q10.

  The content of coenzyme Q10 in medicines and foods is not limited as long as it is an amount that can prevent and / or improve the metabolic syndrome or the disease caused by metabolic syndrome. The amount is such that the intake is 1 to 2000 mg, preferably 10 to 500 mg, more preferably 30 to 300 mg.

  Coenzyme Q10 is a lipophilic solid having a low melting point, and is known to have low absorbability in oral administration due to poor solubility in water. For this reason, it is preferable to improve stability of properties such as dispersion stability of coenzyme Q10 in pharmaceutical preparations and foods, and prevention of crystal precipitation, and bioabsorbability. In the present invention, a stabilized product of coenzyme Q10 may be used. For example, coenzyme Q10 is blended with animal protein such as chicken egg protein, milk protein, meat protein, vegetable protein such as soy protein or soy peptide, or a hydrolyzate thereof, or further blended with sugar such as starch. By doing so, it may be used after coenzyme Q10 is stabilized and bioabsorbability is further improved.

  When coenzyme Q10 is used as an emulsified composition, for example, coenzyme Q10 is dissolved in a sucrose fatty acid ester such as sucrose acetate isobutyric acid ester, poly (mono) glycerol fatty acid ester, etc. as an oil phase component, and a polyhydric alcohol and an emulsifier Or gum arabic, agar, water-soluble corn fiber, starch, gelatin, xanthan gum, casein, dextrin, carmellose sodium, polyvinylpyrrolidone in the presence or absence of additives such as organic acids Coenzyme Q10 may be dispersed and emulsified in a water-soluble substance such as, or incorporated into an inclusion compound such as cyclodextrin, and then used after improving the stable bioabsorbability of properties.

  The subject who takes the preventive and / or ameliorating agent, composition or food for the metabolic syndrome or the disease caused by the metabolic syndrome according to the present invention is a human or an animal. In the present invention, animals refer to industrial animals, companion animals, and experimental animals. Industrial animals include domestic animals such as cattle, horses, pigs, goats and sheep, domestic fowls such as chickens, ducks, quails, turkeys and ostriches, and fish such as yellowtail, yellowtail, red sea bream, red sea bream, carp, rainbow trout and eel. It is an animal that is needed to do. A companion animal refers to a domestic pet such as a dog, a cat, or a marmoset. Laboratory animals refer to animals shared for research in fields such as medicine, biology, agriculture, pharmacy, such as beagle dogs, miniature pigs, rhesus monkeys, and cynomolgus monkeys.

The metabolic syndrome referred to in the present invention is also called multiple risk factor syndrome, and refers to a state in which lifestyle-related diseases such as hyperlipidemia, hypertension, diabetes, and obesity are easily caused.
The present invention is not limited at all as long as it is a metabolic syndrome or a disease symptom or disease caused by metabolic syndrome that is a subject of the present invention. Examples of metabolic syndrome or diseases caused by metabolic syndrome include hyperlipidemia, hypertension, diabetes, obesity, diabetic retinopathy, diabetic cataract, diabetic nephropathy, arteriosclerosis, myocardial infarction, cerebral infarction, etc. Combinations are listed.

  The composition containing coenzyme Q10 of the present invention as an active ingredient may be a composition effective for the prevention and / or improvement of metabolic syndrome or a disease caused by metabolic syndrome by ingestion and / or application. A metabolic syndrome or a method for preventing and / or ameliorating a disease caused by metabolic syndrome characterized by ingesting and / or applying the composition is also within the scope of the present invention. Ingestion includes both oral and parenteral, and parenteral includes injection, infusion, and nasal administration.

  The use of coenzyme Q10 of the present invention is not particularly limited as long as it is used for preparing metabolic syndrome or a composition for preventing and / or improving diseases caused by metabolic syndrome. Examples of compositions effective for the prevention and / or improvement of metabolic syndrome or a disease caused by metabolic syndrome include a drug as a preventive and / or ameliorating agent for a disease caused by metabolic syndrome or metabolic syndrome, and a metabolic syndrome or metabolic syndrome. Examples thereof include functional foods and cosmetics that have an effect of preventing and / or improving the disease caused by the disease.

  The pharmaceutical containing coenzyme Q10 of the present invention is not limited at all as long as it can prevent and / or ameliorate metabolic syndrome or a disease caused by metabolic syndrome. The pharmaceutical dosage form includes scattered, granule, pill, soft capsule, hard capsule, tablet, chewable tablet, quick-disintegrating tablet, syrup, liquid, suspension, suppository, ointment, cream, gel, sticky Agents, inhalants, injections and the like. These preparations are prepared according to conventional methods. However, since Coenzyme Q10 is hardly soluble in water, it can be dissolved in a non-hydrophilic organic solvent such as vegetable oil or animal oil, or an emulsifier, dispersed or surfactant Along with the agent, etc., it is used after being dispersed and emulsified in an aqueous solution using a homogenizer (high pressure homogenizer). Further, in order to increase the absorbability of coenzyme Q10, the average particle system can be finely pulverized to about 1 micron.

  Additives that can be used for formulation include animal oils such as soybean oil, safflower oil, olive oil, germ oil, sunflower oil, beef tallow, sardine oil, polyethylene glycol, propylene glycol, glycerin, sorbitol, etc. Surfactant such as polyhydric alcohol, sorbitan fatty acid ester, sucrose fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, purified water, lactose, starch, crystalline cellulose, D-mannitol, lecithin, gum arabic, sorbitol solution, sugar Examples thereof include excipients such as liquid, sweeteners, colorants, pH adjusters, and fragrances. The liquid preparation may be dissolved or suspended in water or other appropriate medium when taken. Tablets and granules may be coated by a known method.

  When administered in the form of an injection, it can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, transdermally, intraarticularly, within the bursa, intravesicular, intraperiosteally, sublingually, orally. In particular, intravenous administration or intraperitoneal administration is preferred. Intravenous administration may be either drip administration or porous administration.

  The functional food containing the coenzyme Q10 of the present invention is not limited in any way as long as the metabolic syndrome or an effect of improving a disease caused by the metabolic syndrome can be obtained. For example, a coenzyme Q10-containing supplement (scattered, granule) Agents, soft capsules, hard capsules, tablets, chewable tablets, quick-disintegrating tablets, syrups, liquids, etc., coenzyme Q10-containing beverages (tea, carbonated beverages, lactic acid beverages, sports drinks, etc.) Chocolate, cookies, candy, etc.), Coenzyme Q10-containing oil, Coenzyme Q10-containing oil and fat food (mayonnaise, dressing, butter, cream, margarine, etc.) Coenzyme Q10-containing ketchup, Coenzyme Q10-containing sauce, Coenzyme Mu Q10-containing liquid food, coenzyme Q10-containing dairy products (milk, yogurt, cheese, etc.), coenzyme Q10-containing breads, coenzyme Q10-containing noodles (udon, soba, ramen, pasta, yakisoba, kishimen, somen, hiyamugi, rice noodles) Etc.).

  The functional food containing coenzyme Q10 used in the present invention includes various nutrients, various vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin D, vitamin E, vitamin K as necessary. Etc.), various minerals (magnesium, zinc, iron, sodium, potassium, selenium, etc.), dietary fiber, polyunsaturated fatty acids (arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid, etc.), conjugated fatty acids (Conjugated linoleic acid, conjugated linolenic acid, etc.), phospholipids (lecithin, phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylcholine, phosphatidylinositol, phosphatidyl DHA, etc.), glycolipids (cerebroside, etc.), carote Ids (β-carotene, lycopene, astaxanthin, β-cryptoxanthin, etc.), flavonoids (quercetin, luteolin, isoflavone, etc.), xanthophylls (capsanthin, lutein, zeaxanthin, etc.), amino acids (glycine, serine, alanine, glutamine) , Valine, leucine, isoleucine, lysine, arginine, aspartic acid, glutamic acid, tryptophan, phenylalanine, histidine, proline, methionine, cysteine, etc., other nutrients (carnitine, sesamin, α-lipoic acid, inositol, D-kyleunositol, Pinitol, taurine, glucosamine, chondroitin sulfate, S-adnosylmethionine, curcumin, γ-oryzanol, glutathione, γ-aminobutyric acid, synephrine, pyrroloquino Nkinon, catechin, capsaicin, etc.), dispersing agents, stabilizers such as emulsifiers, sweeteners, taste components (citric acid, malic acid), can be blended flavor, royal jelly, propolis, agaricus, and the like. Moreover, you may mix | blend herbs, such as peppermint, bergamot, camomile meal, and lavender. Moreover, you may mix | blend raw materials, such as theanine, a dehydroepiandosterone, and melatonin. Moreover, there is no problem even if reduced coenzyme Q10 produced from oxidized coenzyme Q10 is contained in the process of processing as food or cosmetics due to physical conditions or other coexisting components.

  Examples of the cosmetic of the present invention include creams, emulsions, lotions, microemulsion essences, bathing agents, and the like, and fragrances and the like may be mixed.

  As a method for evaluating the prevention and / or improvement degree of a disease caused by metabolic syndrome or metabolic syndrome, any method may be used as long as it is a method for evaluating the prevention and / or improvement degree of a disease caused by metabolic syndrome or metabolic syndrome. For example, metabolic syndrome Using SHR / NDmcr-cp (SHR / cp), which is a model animal, their body weight, heart rate, blood pressure, glucose, lipoprotein (HDL; high density lipoprotein, LDL; low density lipoprotein, VLDL; etc.) ), Oxidized LDL, CRP, 8-hydroxydeoxyguanosine (8-OHdG), FRAS, BAP, ORAC, lipid peroxide, malondialdehyde (TBARS), carboxymethyllysine, pentosidine, hexanoyllysine, 4-hydroxynonenal, Chlorine, 3-nitrotyrosine (3-NT), 3-chlorotyrosine (3-CT), total cholesterol, blood free fatty acid, coenzyme Q10 oxidation rate, glutathione peroxidase, superoxide dismutase, and catalase activity are measured. That's fine.

The present invention will be described based on formulation examples, food production examples, cosmetic production examples, and examples, but the present invention is not limited to the following examples.
[Formulation Example 1]
<Tablets>
Coenzyme Q10 120g
Crystalline cellulose 330g
Carmellose-calcium 15g
Hydroxypropylcellulose 10g
60 ml of purified water
The above composition was blended and dried in the usual manner, 10 g of magnesium stearate was added, and tableting was performed to obtain 100 mg tablets containing 20 mg of coenzyme Q10 per tablet.

[Formulation Example 2]
<Soft capsule>
200 g of coenzyme Q10 was added to 400 g of olive oil, dissolved at about 60 ° C., stirred uniformly, and then cooled to obtain a coenzyme Q10-containing material. Gelatin 70% and glycerin 30% were mixed and swollen to prepare a dissolved gelatin sheet. This gelatin sheet was filled with a coenzyme Q10-containing material as an internal solution so as to have an internal volume of 300 mg per capsule and dried to obtain soft capsules containing 100 mg of coenzyme Q10 per capsule.

[Food Production Example 1]
<Beverage>
30 g of coenzyme Q10 was heated to 60 ° C. to obtain an oil phase. 10 g of glycerol fatty acid ester as an emulsifier was added to 90 g of glycerin and heated to 70 ° C. to dissolve. The previous oil phase was gradually added to this solution with stirring. The mixed solution was subjected to high-pressure emulsification using an emulsifier to obtain an emulsified composition. To 20 g of this emulsified composition, 180 ml of water was added and stirred to obtain a coenzyme Q10-containing beverage.

[Food Production Example 2]
<Bread>
1 g of coenzyme Q10, 15 g of sugar, 2 g of salt and 5 g of fat powdered milk were dissolved in 70 g of hot water, and 2 eggs were added and mixed well. This was added to a mixture of 130 g of wheat flour and 2 g of dry yeast, kneaded by hand, then kneaded with about 30 g of butter to make 30 roll bread dough. Next, after fermenting, a beaten egg was applied to the surface and baked in an oven at 180 ° C. for 15 minutes to obtain a roll.

[Food Production Example 3]
<Udon>
To 400 g of wheat flour, 2 g of coenzyme Q10 and 20 g of sodium chloride were added to 200 g of water and kneaded well. Thereafter, the dough was stretched and cut into widths of about 6 mm to produce udon.

[Cosmetics Production Example 1]
<Cream>
Coenzyme Q10, stearyl alcohol, propylene glycol, sorbitol, paraben, vitamin E, fragrance, and purified water were blended in appropriate amounts according to a conventional method to obtain a cream.

[Example 1]
6-week-old male SHR / NDmcr-cp (SHR / cp) rats (for example, can be purchased from Nippon SLC Co., Ltd.) commercially available standard diet or various concentrations (0.07, 0.2 and 0) 7%) coenzyme Q10 supplemented diet, and each group used 6 animals as control group, 0.07% coenzyme Q10 group, 0.2% coenzyme Q10 group and 0.7% coenzyme Q10 group It was. The systolic blood pressure of the tail artery was measured by tail-cuff method every 4 weeks without anesthesia. Also, blood was collected from the tail vein after fasting for 12 hours, 8-hydroxydeoxyguanosine (8-OHdG) indicating the degree of degeneration of LDL, which is a marker of oxidative stress, lipid peroxide and DNA, and reactive nitrogen oxide biomarkers Each blood concentration of 3-nitrotyrosine (3-NT) and 3-chlorotyrosine (3-CT) was measured. Furthermore, high-sensitivity C-reactive protein (hsCRP), which is said to be a predictor of the onset of myocardial infarction and diabetes as a marker of inflammatory reaction, and insulin level in blood were measured as an index of insulin resistance.

  The degree of denaturation of LDL was determined by subfraction analysis using anion exchange HPLC (AE-HPLC) (Yamaguchichi Y et. Al .: Atherocleosis 139, 323-331 (1998), Haginaka J. et al., J. Biol. Chromatogr.B.751, 161-167 (2001)). The lipid peroxide value was measured by the Yagi method (Yagi K .: Biochem. Med. 15, 212-216 (1976)) and expressed as the amount of thiobarbituric acid reactive substances (TBARS). The amount of 8-OHdG in serum was determined by HPLC (HPLC-ECD) method using a multi-electrode electrochemical detector (Long et al., J. Chromatogr. B. 731, 241-249 (1999)). It was measured. The amount of 3-NT and 3-CT in serum total protein was determined by HPLC-ECD method (Yamaguchi Y. et al., FEBS Lett. 512, 218-222 (2002)). Displayed. The hsCRP and insulin values were measured using a commercially available ELISA kit (Alpha Diagnostic and Morinaga Bioscience Institute).

  The effect of coenzyme Q10 administration on blood pressure is shown in FIG. In particular, in the drawing, coenzyme Q10 may be abbreviated as CoQ10. The systolic blood pressure of the SHR / cp control group was 150 mmHg or more at 6 weeks of age, had already developed hypertension, increased with aging, and continued until 28 weeks of age. In contrast, administration of coenzyme Q10 was found to have a significant blood pressure increase-inhibiting effect in a concentration-dependent manner.

  The effect of coenzyme Q10 administration on 8-OHdG is shown in FIG. In the control group, the 8-OHdG value of the oxidative stress marker already showed a high value at 6 weeks of age, increased with aging, plateaued at 16-20 weeks of age, and then tended to decrease. In contrast, in the coenzyme Q10 administration group, the increase in 8-OHdG value was suppressed in a concentration-dependent manner. This result has been found to have an effect of suppressing DNA oxidative damage. Therefore, coenzyme Q10 is effective in preventing arteriosclerosis and the like due to increased metabolic syndrome oxidation.

  The effect of coenzyme Q10 administration on the oxidized LDL level is shown in FIG. In the control group, oxidized LDL showed a high value at 6 weeks of age. In contrast, the increase in oxidized LDL was significantly suppressed in the coenzyme Q10 administration group. From this result, it was found that coenzyme Q10 has an effect of suppressing oxidative stress. Therefore, coenzyme Q10 is effective in preventing arteriosclerosis and the like due to increased metabolic syndrome oxidation.

  The effect of coenzyme Q10 administration on 3-NT and 3-CT values is shown in FIG. In the control group, the 3-NT and 3-CT values did not change at 6 and 8 weeks of age, but both showed an increasing trend at 16 weeks of age and then increased significantly with aging. These increases were significantly suppressed in the coenzyme Q10 administration group. From this result, it was found that coenzyme Q10 has an effect of reducing reactive nitrogen oxides. Here, reactive nitrogen oxides such as 3-NT and 3-CT are known to suppress phosphorylation in the body and induce apoptosis. In addition, since it exists in many lesions of arteriosclerosis, it is expected to be involved in the progression of arteriosclerosis. Furthermore, it is known to be involved in Alzheimer's syndrome, Parkinson's disease, and acute lung injury. Therefore, the above pathological condition can be improved or prevented by administering Coenzyme Q10.

  FIG. 5 shows the effect of coenzyme Q10 administration on insulin levels. The control group showed a markedly higher value at 6 weeks of age compared to normal rats, but increased with age and peaked at 20 weeks of age. Such a marked increase was significantly suppressed in the coenzyme Q10 administration group in a concentration-dependent manner. From this result, it was found that coenzyme Q10 has an effect of improving diabetes that develops as metabolic syndrome, and is effective in preventing diabetes caused by metabolic syndrome.

  The effect of coenzyme Q10 administration on the high sensitivity CRP value is shown in FIG. The control group was similar to normal rats at 6 weeks of age, but showed an increasing trend at 12 weeks of age, increased with aging and reached a peak at 20 weeks of age, but almost normal at 32 weeks of age. Decreased to. The increase in the high-sensitivity CRP value observed between 16 and 20 weeks of age was significantly suppressed in a coenzyme Q10 administration group in a concentration-dependent manner. From this result, it was found that coenzyme Q10 has an effect of improving myocardial infarction and diabetes, and is effective in preventing myocardial infarction and diabetes caused by metabolic syndrome.

  The metabolic syndrome characterized by containing coenzyme Q10 of the present invention as an active ingredient or a functional food having a disease-ameliorating effect caused by metabolic syndrome can be suitably used in the field of medicine and / or food.

The coenzyme Q10 administration effect on the blood pressure of a metabolic syndrome model rat is shown. The coenzyme Q10 administration effect with respect to 8-OHdG of a metabolic syndrome model rat is shown. The coenzyme Q10 administration effect with respect to the oxidation LDL level of a metabolic syndrome model rat is shown. The coenzyme Q10 administration effect with respect to 3-NT and 3-CT value of a metabolic syndrome model rat is shown. The coenzyme Q10 administration effect with respect to the insulin level of a metabolic syndrome model rat is shown. The coenzyme Q10 administration effect with respect to the highly sensitive CRP value of a metabolic syndrome model rat is shown.

Claims (10)

  A preventive and / or ameliorating agent for metabolic syndrome or a disease caused by metabolic syndrome, comprising coenzyme Q10 as an active ingredient.   Metabolic syndrome containing coenzyme Q10 as an active ingredient or a functional food having an effect of preventing and / or improving diseases caused by metabolic syndrome.   Use of coenzyme Q10 for producing a metabolic syndrome or a composition for preventing and / or ameliorating a disease caused by metabolic syndrome.   Use of coenzyme Q10 for prevention and / or amelioration of metabolic syndrome or a disease caused by metabolic syndrome.   A method for preventing and / or improving metabolic syndrome or a disease caused by metabolic syndrome, comprising ingesting or applying a composition containing coenzyme Q10 as an active ingredient.   The preventive and / or ameliorating agent according to claim 1, wherein the disease caused by metabolic syndrome is arteriosclerosis.   The functional food according to claim 2, wherein the disease caused by metabolic syndrome is arteriosclerosis.   The use of coenzyme Q10 according to claim 4, wherein the disease caused by metabolic syndrome is arteriosclerosis.   The method for prevention or improvement according to claim 5, wherein the disease caused by metabolic syndrome is arteriosclerosis.   A preventive or ameliorating agent for metabolic syndrome or a disease caused by metabolic syndrome by improving at least one symptom of hypertension, oxidative stress, inflammation, or insulin resistance, comprising coenzyme Q10 as an active ingredient.